Verano: Analysts Expect Q3 Revenues Of $219.7 Million

Verano Holdings (CSE: VRNO) announced that they will be reporting their third quarter financials before the market opens on November 16th.

Analysts have a consensus C$40.38 12-month price target on the company, via a total of 7 analysts, with 2 analysts having strong buy ratings, and the other 5 having buy ratings on the company. The street high comes from Beacon Securities with a C$47 price target, and the lowest target sits at C$35.

7 analysts have revenue estimates for the third quarter. The mean between all 7 is US$219.70 million; this number has been revised slightly down from US$224.82 million at the start of May. The street high is US$224.60 million while the lowest sits at US$210 million.

7 analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 55.41%, with this number revised down from 60.72% at the start of May. Street high is a 58% estimate and the lowest sits at 53%.

Onto EBITDA estimates, there are currently 7 analysts who have third-quarter EBITDA estimates. The mean is currently US$85.64 million, with this number being revised down from US$100.17 million since the start of May. Street high sits at US$93.50 million EBITDA and the lowest being a US$63.70 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

SSR Mining Walks Away From a World Class Gold-Copper Project

Why More Canadians Are Starting to Think About Leaving | Jesse Day

Instead of Waiting, This Gold Developer Went Bigger | Kenneth McLeod – Sonoro Gold

Recommended

Amid CBS Shuffle, Is Joe Rogan Replacing Anderson Cooper On 60 Minutes?

Silver47 Targets Resource Growth With 10,000 Metre Red Mountain Drill Program

Related News

MediPharm Labs: Canaccord Resumes Coverage, Issues $2.25 Price Target

As a follow up to the earlier covered resumption of coverage by Canaccord Genuity on...

Monday, July 6, 2020, 04:53:00 PM

BMO Cuts Price Target On Salesforce On Disappointing Guidance

Salesforce (NYSE: CRM) last week reported it’s third-quarter financial results for the period ending October...

Wednesday, December 7, 2022, 03:50:00 PM

Columbia Care Sees Consensus Price Target Rise To $14.70

On August 12, Columbia Care Inc. (CSE: CCHW) reported its second-quarter financial results, wherein the...

Wednesday, August 18, 2021, 10:09:00 AM

Harvest Health Announces Definitive Agreement to Purchase Verano Holdings

Last night, it was announced that Harvest Health and Recreation (CSE: HARV) had signed a...

Wednesday, April 24, 2019, 07:30:02 AM

Ayr Wellness: Canaccord Reiterates Ratings After Quarterly Results

On August 16, Ayr Wellness (CSE: AYR.a) reported their second quarter financial results. The company...

Thursday, August 26, 2021, 10:24:00 AM